Industry Primer — Healthcare
Medical aesthetics encompasses injectable neurotoxins (Botox), dermal fillers, body contouring devices, skin rejuvenation lasers, and cosmetic dermatology services. The global medical aesthetics market exceeds $20 billion and is growing at 10-12% annually. AbbVie (via Allergan) dominates with Botox and the Juvederm filler portfolio. The sector is attractive for investors due to cash-pay economics (no insurance dependency), high margins, recurring treatment cycles, and expanding demographics as treatments become mainstream among younger patients and men.
Demand is robust, with neurotoxin and filler volumes growing above pre-COVID trends. The competitive landscape is intensifying — new neurotoxins (Daxxify with longer duration, Letybo) and biosimilar Botox candidates are expanding options. GLP-1-related skin laxity from rapid weight loss is creating a new demand wave for body contouring and skin tightening procedures. Direct-to-consumer marketing and social media influence are driving awareness and demand among younger demographics.
Over five years, medical aesthetics will grow 10-15% annually. Treatment adoption will expand geographically (tier-2/3 cities) and demographically (men, younger patients, diverse skin types). Energy-based devices for non-invasive body contouring, skin tightening, and hair removal will improve, capturing procedures from surgical alternatives. Combination treatment protocols and subscription/membership models will increase per-patient revenue. Regenerative aesthetics using PRP, exosomes, and stem cell-derived products will emerge.
Long-term, medical aesthetics will become as routine as dental care for a significant portion of the population. Anti-aging science advances may create entirely new treatment categories — senolytics, NAD+ therapies, and gene expression modifiers. AI-powered treatment planning using facial analysis and simulation will personalize protocols. The key risk is regulatory — the FDA could tighten oversight of medical spas and non-physician practitioners, constraining access points.
Consumer disposable income directly correlates with elective aesthetic spending. Practitioner supply — dermatologists, plastic surgeons, nurse injectors — determines capacity. Product innovation cycle drives treatment upgrades and new patient acquisition. Social media and influencer marketing impact demand generation. Regulatory oversight of medical spas and non-physician injectors varies by state. Competitive intensity from new product entrants affects pricing power.
AI is enhancing aesthetics through facial analysis tools that recommend personalized treatment plans, before/after simulation that improves consultation conversion rates, automated patient engagement and follow-up, and treatment outcome tracking across large patient datasets. AI-powered skin analysis apps can assess aging patterns and suggest preventive treatments. Robotic injection assistance for precise neurotoxin and filler placement is in early development.
Medical aesthetics practices can deploy CRM and marketing automation platforms tailored to the cosmetic patient journey — automated consultations, treatment reminders, loyalty programs — to drive repeat visits and referrals. AI-powered facial analysis tools improve treatment planning and patient education, increasing case acceptance. Centralized scheduling and inventory management across multi-location portfolios optimize provider utilization and product ordering. Membership and subscription platforms create predictable recurring revenue.
AbbVie (ABBV) owns Allergan Aesthetics (Botox, Juvederm, CoolSculpting). InMode (INMD) manufactures minimally invasive energy-based devices. Evolus (EOLS) markets Jeuveau neurotoxin. Revance Therapeutics (RVNC) developed Daxxify, a longer-lasting neurotoxin. Cutera (CUTR) makes laser and energy-based aesthetic devices. The Beauty Health Company (SKIN) owns HydraFacial.